

February 9, 2018
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Termination of the Development
of the Patient-controlled Pain Management Drug “SyB P-1501”**

TOKYO, Japan, February 9, 2018 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") announced today the completion of the termination of the development of “IONSYS” or “SyB P-1501” in Japan, a drug for patient-controlled, short-term management of acute postoperative pain during hospitalization. SymBio was developing “SyB P-1501” in Japan under a license agreement entered into on October 2, 2015 between SymBio and and The Medicines Company (Headquarters: Parsippany, New Jersey, “MDCO”), which terminated effective November 30, 2017. SymBio initiated an arbitration against MDCO on October 11, 2017, under the rules of International Chamber of Commerce, seeking damages of US\$ 82 million (approximately JPY 9 billion) arising out of MDCO’s repudiation of the license agreement. This will not impact SymBio’s current financial forecast or the mid-range plan posted on February 7, 2018.

< Related press releases >

*November 13, 2017 : Initiation of an Arbitration against The Medicines Company

*November 30, 2017 : Termination of License Agreement between SymBio Pharmaceuticals and The Medicines Company

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016 the SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.